Single dose vaccination of the ASO3-adjuvanted A (H1N1)pdm09 monovalent vaccine in health care workers elicits homologous and cross-reactive cellular and humoral responses to H1N1 strains

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 7, 2015, Pages 1654-1662

  Lartey, Sarah ^a,b   Pathirana, Rishi D ^a,b   Zhou, Fan ^a   Jul Larsen, Åsne ^a,b   Montomoli, Emanuele ^c,d   Wood, John ^e   Cox, Rebecca Jane ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF SIENA   (Italy)

^d VisMederi Srl   (Italy)

^e NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

AS03; Cross reactivity; H1N1; Healthcare workers; Immune responses; Pandemic influenza; Vaccination

Indexed keywords

AS03 ADJUVANTED MONOVALENT SPLIT VIRUS VACCINE; GAMMA INTERFERON; HEMAGGLUTININ; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS VACCINE; ALPHA TOCOPHEROL; ASO3B ADJUVANT; DRUG COMBINATION; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; POLYSORBATE; SQUALENE; VIRUS ANTIBODY;

ANTIBODY SECRETING CELL; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CROSS REACTION; CYTOKINE RESPONSE; ENZYME LINKED IMMUNOSPOT ASSAY; HEALTH CARE PERSONNEL; HEMOLYSIS; HUMAN; HUMORAL IMMUNITY; INFLUENZA A VIRUS (H1N1); MEMORY CELL; SINGLE DRUG DOSE; TH1 CELL; VACCINATION; ADULT; BLOOD; CLINICAL TRIAL; DRUG COMBINATION; FEMALE; HEMAGGLUTINATION INHIBITION TEST; IMMUNIZATION; IMMUNOLOGY; INFLUENZA, HUMAN; MALE; MIDDLE AGED; TIME FACTOR;

ADJUVANTS, IMMUNOLOGIC; ADULT; ALPHA-TOCOPHEROL; ANTIBODIES, VIRAL; CROSS REACTIONS; DRUG COMBINATIONS; FEMALE; HEALTH PERSONNEL; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNIZATION SCHEDULE; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; INTERFERON-GAMMA; MALE; MIDDLE AGED; POLYSORBATES; SQUALENE; TIME FACTORS;

EID: 84944458406     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1048939     Document Type: Article

References (44)

1. Brockwell-Staats C, Webster RG, Webby RJ. Diversity of influenza viruses in swine and the emergence of a novel human pandemic influenza A (H1N1). Influen Other Res Viruses 2009; 3:207-13; PMID:19768134; http://dx. doi. org/10. 1111/j. 1750-2659. 2009. 00096. x
2. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, Liu F, Dong L, DeVos JR, Gargiullo PM, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Eng J Med 2009; 361:1945-52; PMID:19745214; http://dx. doi. org/ 10. 1056/NEJMoa0906453
3. Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ, Gubareva LV, Xu X, Bridges CB, Uyeki TM. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Eng J Med 2009; 360:2605-15; PMID:19423869; http://dx. doi. org/ 10. 1056/NEJMoa0903810
4. Madhun AS, Akselsen PE, Sjursen H, Pedersen G, Svindland S, Nostbakken JK, Nilsen M, Mohn K, Jul- Larsen A, Smith I, et al. An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. Vaccine 2010; 29:266- 73; PMID:21034828; http://dx. doi. org/10. 1016/j. vaccine. 2010. 10. 038
5. Gerhard W. The role of the antibody response in influenza virus infection. Curr Topics Microbiol Immunol 2001; 260:171-90; PMID:11443873
6. Li GM, Chiu C, Wrammert J, McCausland M, Andrews SF, Zheng NY, Lee JH, Huang M, Qu X, Edupuganti S, et al. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc Natl Acad Sci U S A 2012; 109:9047-52; PMID:22615367; http://dx. doi. org/10. 1073/pnas. 1118979109
7. Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, Morrissey M, McCausland M, Skountzou I, Hornig M, Lipkin WI, et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 2011; 208:181-93; PMID:21220454; http://dx. doi. org/10. 1084/jem. 20101352
8. Pica N, Hai R, Krammer F, Wang TT, Maamary J, Eggink D, Tan GS, Krause JC, Moran T, Stein CR, et al. Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc Natl Acad Sci U S A 2012; 109:2573-8; PMID:22308500; http:// dx. doi. org/10. 1073/pnas. 1200039109
9. Thomson CA, Wang Y, Jackson LM, Olson M, Wang W, Liavonchanka A, Keleta L, Silva V, Diederich S, Jones RB, et al. Pandemic H1N1 Influenza Infection and Vaccination in Humans Induces Cross-Protective Antibodies that Target the Hemagglutinin Stem. Front Immunol 2012; 3:87; PMID:22586427; http://dx. doi. org/10. 3389/fimmu. 2012. 00087
10. Greenbaum JA, Kotturi MF, Kim Y, Oseroff C, Vaughan K, Salimi N, Vita R, Ponomarenko J, Scheuermann RH, Sette A, et al. Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci U S A 2009; 106:20365-70; PMID:19918065; http://dx. doi. org/10. 1073/pnas. 0911580106
11. Sridhar S, Begom S, Bermingham A, Hoschler K, Adamson W, Carman W, Bean T, Barclay W, Deeks JJ, Lalvani A. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med 2013; 19:1305-12; PMID:24056771; http://dx. doi. org/10. 1038/nm. 3350
12. Ferguson M, Risi G, Davis M, Sheldon E, Baron M, Li P, Madariaga M, Fries L, Godeaux O, Vaughn D. Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant. J Infect Dis 2012; 205:733-44; PMID:22315336; http://dx. doi. org/10. 1093/infdis/jir641
13. Ikematsu H, Nagai H, Kawashima M, Kawakami Y, Tenjinbaru K, Li P, Walravens K, Gillard P, Roman F. Characterization and long-term persistence of immune response following two doses of an AS03A-adjuvanted H1N1 influenza vaccine in healthy Japanese adults. Hum Vaccin Immunother 2012; 8:260-6; PMID:22426369; http://dx. doi. org/10. 4161/hv. 18469
14. Ikematsu H, Tenjinbaru K, Li P, Madan A, Vaughn D. Evaluation of immune response following one dose of an AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in Japanese adults 65 years of age or older. Hum Vaccin Immunother 2012; 8:1119-25; PMID:22854661; http://dx. doi. org/10. 4161/hv. 21081
15. Pathirana RD, Bredholt G, Akselsen PE, Pedersen GK, Cox RJ. A(H1N1)pdm09 vaccination of health care workers: improved immune responses in low responders following revaccination. J Infect Dis 2012; 206:1660-9; PMID:22969149; http://dx. doi. org/ 10. 1093/infdis/jis589
16. Poder A, Simurka P, Li P, Roy-Ghanta S, Vaughn D. An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age. Vaccine 2014; 32:1121-9; PMID:24252703; http://dx. doi. org/ 10. 1016/j. vaccine. 2013. 11. 031
17. Roy-Ghanta S, Van der Most R, Li P, Vaughn DW. Responses to A(H1N1)pdm09 Influenza Vaccines in Participants Previously Vaccinated With Seasonal Influenza Vaccine: A Randomized, Observer-Blind, Controlled Study. J Infect Dis 2014; 210:1419-30; PMID:24864125; http://dx. doi. org/10. 1093/infdis/jiu284
18. Saitoh A, Nagai A, Tenjinbaru K, Li P, Vaughn DW, Roman F, Kato T. Safety and persistence of immunological response 6 months after intramuscular vaccination with an AS03-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized trial in Japanese children aged 6 months to 17 years. Hum Vaccin Immunother 2012; 8:749-58; PMID:22495117; http://dx. doi. org/10. 4161/hv. 19684
19. Van Damme P, Kafeja F, Bambure V, Hanon E, Moris P, Roman F, Gillard P. Long-term persistence of humoral and cellular immune responses induced by an AS03A-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized study in adults aged 18- 60 years and older. Hum Vaccin Immunother 2013; 9:1512-22; PMID:23571166; http://dx. doi. org/ 10. 4161/hv. 24504
20. Yang WH, Dionne M, Kyle M, Aggarwal N, Li P, Madariaga M, Godeaux O, Vaughn DW. Long-term immunogenicity of an AS03-adjuvanted influenza A (H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial. Vaccine 2013; 31:4389-97; PMID:23856331; http://dx. doi. org/ 10. 1016/j. vaccine. 2013. 07. 007
21. Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br Med Bull 1979; 35:69- 75; PMID:367490
22. Wood JM, Gaines-Das RE, Taylor J, Chakraverty P. Comparison of influenza serological techniques by international collaborative study. Vaccine 1994; 12:167-74; PMID:8147099; http://dx. doi. org/ 10. 1016/0264-410X(94)90056-6
23. Cox RJ, Brokstad KA, Zuckerman MA, Wood JM, Haaheim LR, Oxford JS. An early humoral immune response in peripheral blood following parenteral inactivated influenza vaccination. Vaccine 1994; 12:993-9; PMID:7975853; http://dx. doi. org/10. 1016/0264- 410X(94)90334-4
24. Dormitzer PR, Galli G, Castellino F, Golding H, Khurana S, Del Giudice G, Rappuoli R. Influenza vaccine immunology. Immunol Rev 2011; 239:167-77; PMID:21198671; http://dx. doi. org/10. 1111/j. 1600- 065X. 2010. 00974. x
25. Bende RJ, vanMaldegemF, TriesscheijnM, Wormhoudt TA, Guijt R, van Noesel CJ. Germinal centers in human lymph nodes contain reactivated memory B cells. J Exp Med 2007; 204:2655-65; PMID:17938234; http://dx. doi. org/10. 1084/jem. 20071006
26. Berkowska MA, Driessen GJ, Bikos V, Grosserichter- Wagener C, Stamatopoulos K, Cerutti A, He B, Biermann K, Lange JF, van der Burg M, et al. Human memory B cells originate from three distinct germinal center-dependent and -independent maturation pathways. Blood 2011; 118:2150-8; PMID:21690558; http://dx. doi. org/10. 1182/blood-2011-04-345579
27. PurthaWE, Tedder TF, Johnson S, BhattacharyaD, Diamond MS. Memory B cells, but not long-lived plasma cells, possess antigen specificities for viral escape mutants. J Exp Med 2011; 208:2599-606; PMID:22162833; http://dx. doi. org/10. 1084/jem. 20110740
28. KrystalM, Elliott RM, Benz EW, Jr., Young JF, Palese P. Evolution of influenza A and B viruses: conservation of structural features in the hemagglutinin genes. Proc Natl Acad Sci U S A 1982; 79:4800-4; PMID:6956892; http://dx. doi. org/10. 1073/pnas. 79. 15. 4800
29. Ellebedy AH, Krammer F, Li GM, Miller MS, Chiu C, Wrammert J, Chang CY, Davis CW, McCausland M, Elbein R, et al. Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans. Proc Natl Acad Sci U S A 2014; 111:13133-8; PMID:25157133; http:// dx. doi. org/10. 1073/pnas. 1414070111
30. Nachbagauer R, Wohlbold TJ, Hirsh A, Hai R, Sjursen H, Palese P, Cox RJ, Krammer F. Induction of broadly reactive anti-hemagglutinin stalk antibodies by anH5N1 vaccine in humans. J Virol 2014; 88:13260-8; PMID:25210189; http://dx. doi. org/10. 1128/JVI. 02133-14
31. La Gruta NL, Turner SJ. T cell mediated immunity to influenza: mechanisms of viral control. Trend Immunol 2014; 35:396-402; PMID:25043801; http://dx. doi. org/10. 1016/j. it. 2014. 06. 004
32. Hill DA, Baron S, Perkins JC, Worthington M, Van Kirk JE, Mills J, Kapikian AZ, Chanock RM. Evaluation of an interferon inducer in viral respiratory disease. Jama 1972; 219:1179-84; PMID:4334380; http://dx. doi. org/10. 1001/jama. 1972. 03190350025006
33. Richman DD, Murphy BR, Baron S, Uhlendorf C. Three strains of influenza A virus (H3N2): interferon sensitivity in vitro and interferon production in volunteers. J Clin Microbiol 1976; 3:223-6; PMID:1270590
34. Seo SH, Webster RG. Tumor necrosis factor alpha exerts powerful anti-influenza virus effects in lung epithelial cells. J Virol 2002; 76:1071-6; PMID:11773383; http://dx. doi. org/10. 1128/JVI. 76. 3. 1071-1076. 2002
35. Brown DM, Lee S, Garcia-Hernandez Mde L, Swain SL. Multifunctional CD4 cells expressing gamma interferon and perforin mediate protection against lethal influenza virus infection. J Virol 2012; 86:6792-803; PMID:22491469; http://dx. doi. org/10. 1128/ JVI. 07172-11
36. Kannanganat S, Ibegbu C, Chennareddi L, Robinson HL, Amara RR. Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells. J Virol 2007; 81:8468-76; PMID:17553885; http:// dx. doi. org/10. 1128/JVI. 00228-07
37. Weaver JM, Yang H, Roumanes D, Lee FE, Wu H, Treanor JJ, Mosmann TR. Increase in IFNgamma(-) IL-2(+) cells in recent human CD4 T cell responses to 2009 pandemic H1N1 influenza. PloS One 2013; 8: e57275; PMID:23526940; http://dx. doi. org/10. 1371/ journal. pone. 0057275
38. Lai W, Yu M, Huang MN, Okoye F, Keegan AD, Farber DL. Transcriptional control of rapid recall by memory CD4 T cells. J Immunol 2011; 187:133-40; PMID:21642544; http://dx. doi. org/10. 4049/ jimmunol. 1002742
39. Groth N, Montomoli E, Gentile C, Manini I, Bugarini R, Podda A. Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: a sequential Phase I and Phase II clinical trial. Vaccine 2009; 27:786-91; PMID:19027046; http://dx. doi. org/ 10. 1016/j. vaccine. 2008. 11. 003
40. Oxford JS, Yetts R, Schild GC. Quantitation and analysis of the specificity of post-immunization antibodies to influenza B viruses using single radial haemolysis. J Hygiene 1982; 88:325-33; PMID:7037949; http://dx. doi. org/10. 1017/S0022172400070170
41. Schild GC, Pereira MS, Chakraverty P. Single-radialhemolysis: a new method for the assay of antibody to influenza haemagglutinin. Applications for diagnosis and seroepidemiologic surveillance of influenza. Bull World Health Organ 1975; 52:43-50; PMID:1082381
42. Crotty S, Aubert RD, Glidewell J, Ahmed R. Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system. J Immunol Methods 2004; 286:111-22; PMID:15087226; http://dx. doi. org/10. 1016/j. jim. 2003. 12. 015
43. Pedersen G, Halstensen A, Sjursen H, Naess A, Kristoffersen EK, Cox RJ. Pandemic influenza vaccination elicits influenza-specific CD4+ Th1-cell responses in hypogammaglobulinaemic patients: four case reports. Scand J Immunol 2011; 74:210-8; PMID:21438900; http://dx. doi. org/10. 1111/j. 1365-3083. 2011. 02561. x
44. Roederer M, Nozzi JL, NasonMC. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry Part A2011; 79:167-74; PMID:21265010; http://dx. doi. org/10. 1002/cyto. a. 21015